Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma

Conclusion: We identified recurrent PRAME deletions and characterized their clinical and functional role in DLBCL. Our findings contribute to the understanding of cell-autonomous and extrinsic roles of PRAME deletions in lymphomagenesis and may lead to the discovery of new therapeutic avenues to simultaneously treat the tumor and the host.DisclosuresGascoyne: NanoString: Patents & Royalties: Named Inventor on a patent licensed to NanoString Technologies. Scott: Janssen: Research Funding; Roche: Research Funding; NanoString: Patents & Royalties: Named Inventor on a patent licensed to NanoString Technologies, Research Funding; Celgene: Consultancy, Honoraria. Steidl: Tioma: Research Funding; Seattle Genetics: Consultancy; Roche: Consultancy; Bristol-Myers Squibb: Research Funding; Juno Therapeutics: Consultancy; Nanostring: Patents & Royalties: patent holding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Takata, K., Ennishi, D., Bashashati, A., Saberi, S., Vigano, E., Healy, S., Nielsen, J. S., Antonio, G. D., Nelson, B. H., Shah, S. P., Connors, J. M., Gascoyne, R. D., Scott, D. W., Steidl, C. Tags: 621. Lymphoma-Genetic/Epigenetic Biology: Functional implications of genetics and epigenetics Source Type: research